argenx Gains 0.32% on $4.2B Sales Surge Despite 21.07% Volume Drop to $0.25B (Rank 483)

Market Snapshot

argenx (ARGX) edged higher by 0.32% on March 10, 2026, despite a 21.07% decline in trading volume to $0.25 billion, which ranked the stock 483rd in market activity for the day. While the modest price gain reflects limited short-term volatility, the sharp drop in volume suggests reduced investor engagement compared to the prior session.

Key Drivers

The biopharmaceutical company’s 2025 performance underscores its transformation into a commercial-stage success story, with net product sales surging 90% year-over-year to $4.2 billion. This milestone marked argenx’s first annual profitability, driven primarily by the global adoption of its flagship therapy, VYVGART (efgartigimod). By year-end 2025, the drug had reached 19,000 patients, including 8,500 in the U.S., reflecting robust demand across key markets. Management attributed this growth to the prefilled syringe’s launch, which simplified administration and attracted 1,000 new prescribers, expanding the drug’s reach in myasthenia gravis (MG) treatment.

Clinical progress further bolstered investor confidence. The Phase III ADAPT-OCULUS trial for ocular MG demonstrated statistically significant improvements in symptoms such as double vision and drooping eyelids, meeting its primary endpoint. This outcome positions argenx to file for regulatory approval in ocular MG, targeting an estimated 60,000-patient U.S. population. The trial’s success aligns with the company’s strategy to broaden VYVGART’s label within MG subtypes, including seronegative MG, where demand is currently unmet. A PDUFA date for seronegative MG is set for May 10, 2026, adding to the near-term catalyst pipeline.

Expansion into chronic inflammatory demyelinating polyneuropathy (CIDP) also highlights argenx’s growth trajectory. VYVGART Hytrulo, approved in 2024, has shown early commercial traction, with 85% of CIDP patients switching from intravenous immunoglobulin (IVIg) therapies. The addressable CIDP market in the U.S. is estimated at 10,000–15,000 patients, offering a second revenue pillar as the company scales its commercial infrastructure. However, analysts note that IVIg remains the entrenched standard of care, requiring sustained physician education to drive broader adoption.

Despite these positives, challenges loom. The FcRn inhibitor class, which includes VYVGART, faces increasing competition from late-stage therapies like UCB’s RYSTIGGO and Johnson & Johnson’s nipocalimab. Additionally, argenx’s valuation remains stretched, trading at 10.4x trailing sales compared to a healthcare sector median of 3.4x. While the company’s $4.4 billion cash balance and operating profitability mitigate near-term risks, investors remain cautious about sustaining growth in a competitive landscape. Pipeline execution beyond MG—such as trials for immune thrombocytopenia and autoimmune myositis—will be critical to justify its premium multiples.

In summary, argenx’s stock performance reflects a blend of strong commercial execution and clinical progress, tempered by valuation concerns and competitive pressures. The coming months will test its ability to capitalize on label expansions and diversify into new indications, with the CIDP and ocular MG markets serving as key inflection points.